Sugi Predict

Sugi Predict / Compounds / SCHEMBL1786736

SCHEMBL1786736

SCHEMBL1786736

CN1CCc2ccc(Nc3nccc(-c4c(-c5cccc(NC(=O)c6cc(Cl)sc6Cl)c5)nc5ccccn45)n3)cc2C1

nearest known ligand 0.76

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ BRAF P15056 6/20 0.76
▸ IGF1R P08069 11/20 0.58
▸ EGFR P00533 5/20 0.58
▸ ERBB2 P04626 5/20 0.58
▸ INSR P06213 3/20 0.51
▸ PLK4 O00444 2/20 0.48
▸ CHEK1 O14757 2/20 0.48
▸ PRKD3 O94806 2/20 0.48
▸ LCK P06239 2/20 0.48
▸ CSF1R P07333 2/20 0.48
▸ ROS1 P08922 2/20 0.48
▸ KIT P10721 2/20 0.48
▸ FGFR1 P11362 2/20 0.48
▸ SRC P12931 2/20 0.48
▸ FLT1 P17948 2/20 0.48
▸ FGFR3 P22607 2/20 0.48
▸ MARK3 P27448 2/20 0.48
▸ KDR P35968 2/20 0.48
▸ FLT3 P36888 2/20 0.48
▸ SYK P43405 2/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1786976 0.92 BRAF (0.79) BRAFIGF1REGFRERBB2INSR
SCHEMBL1789815 0.91 BRAF (0.76) BRAFIGF1REGFRERBB2INSR
SCHEMBL1788022 0.89 BRAF (0.88) BRAFIGF1REGFRERBB2INSR
SCHEMBL1787217 0.88 BRAF (0.75) BRAFIGF1REGFRERBB2INSR
SCHEMBL1789389 0.88 BRAF (0.77) BRAFIGF1REGFRERBB2INSR
SCHEMBL1786566 0.88 BRAF (0.85) BRAFIGF1REGFRERBB2INSR
SCHEMBL1789452 0.88 BRAF (0.79) BRAFIGF1REGFRERBB2INSR
SCHEMBL1787233 0.87 BRAF (0.87) BRAFIGF1REGFRERBB2INSR
SCHEMBL1787751 0.87 BRAF (0.76) BRAFIGF1REGFRERBB2INSR
SCHEMBL1788248 0.87 BRAF (0.82) BRAFIGF1REGFRERBB2INSR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9051315-B2 Imidazopyridines as a novel scaffold for multi-targeted kinase inhibition ABBVIE INC. (US) 2015-06-09 — — US claimed
EP-2496574-A1 IMIDAZOPYRIDINES AS A NOVEL SCAFFOLD FOR MULTI-TARGETED KINASE INHIBITION Abbott Laboratories (US) 2012-09-12 — — EP claimed
US-20110124632-A1 IMIDAZOPYRIDINES AS A NOVEL SCAFFOLD FOR MULTI-TARGETED KINASE INHIBITION ABBOTT LABORATORIES (US) 2011-05-26 — — US claimed
WO-2011053476-A1 IMIDAZOPYRIDINES AS A NOVEL SCAFFOLD FOR MULTI-TARGETED KINASE INHIBITION ABBOTT LABORATORIES (US) 2011-05-05 — — WO claimed
US-9051315-B2 Imidazopyridines as a novel scaffold for multi-targeted kinase inhibition ABBVIE INC. (US) 2015-06-09 — — US disclosed
EP-2496574-A1 IMIDAZOPYRIDINES AS A NOVEL SCAFFOLD FOR MULTI-TARGETED KINASE INHIBITION Abbott Laboratories (US) 2012-09-12 — — EP disclosed
US-20110124632-A1 IMIDAZOPYRIDINES AS A NOVEL SCAFFOLD FOR MULTI-TARGETED KINASE INHIBITION ABBOTT LABORATORIES (US) 2011-05-26 — — US disclosed
WO-2011053476-A1 IMIDAZOPYRIDINES AS A NOVEL SCAFFOLD FOR MULTI-TARGETED KINASE INHIBITION ABBOTT LABORATORIES (US) 2011-05-05 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110124632-A1 IMIDAZOPYRIDINES AS A NOVEL SCAFFOLD FOR MULTI-TARGETED KINASE INHIBITION PACSIN2, MAP4K2, MAP3K6 BRAF 226/4885IGF1R 937/4885EGFR 1013/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.